Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
RAD9A N/A
Sequence Length (AA) Molecular Weight (Da)
391 42547
Protein Name
Cell cycle checkpoint control protein RAD9A
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MKCLVTGGNV KVLGKAVHSL SRIGDELYLE PLEDGLSLRT VNSSRSAYAC
60 70 80 90 100
FLFAPLFFQQ YQAATPGQDL LRCKILMKSF LSVFRSLAML EKTVEKCCIS
110 120 130 140 150
LNGRSSRLVV QLHCKFGVRK THNLSFQDCE SLQAVFDPAS CPHMLRAPAR
160 170 180 190 200
VLGEAVLPFS PALAEVTLGI GRGRRVILRS YHEEEADSTA KAMVTEMCLG
210 220 230 240 250
EEDFQQLQAQ EGVAITFCLK EFRGLLSFAE SANLNLSIHF DAPGRPAIFT
260 270 280 290 300
IKDSLLDGHF VLATLSDTDS HSQDLGSPER HQPVPQLQAH STPHPDDFAN
310 320 330 340 350
DDIDSYMIAM ETTIGNEGSR VLPSISLSPG PQPPKSPGPH SEEEDEAEPS
360 370 380 390 391
TVPGTPPPKK FRSLFFGSIL APVRSPQGPS PVLAEDSEGE G

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-5930 Collapse assay details

Data source: Panorama

Official Gene Symbol
RAD9A
Peptide Sequence
SPQGPSPVLAEDSEGEG
Modification Type
unmodified
Protein - Site of Modification
375
Peptide - Site of Modification
N/A
Peptide Start
375
Peptide End
391
CPTAC ID
CPTAC-5930
Peptide Molecular Mass
1,654.7322
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Cell Lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition. Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, Ivey RG, Huang D, Lin C, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Kaczmarczyk JA, Blonder J, Reading JJ, Richardson CW, Hewitt SM, Garcia-Buntley SS, Bocik W, Hiltke T, Rodriguez H, Harrington EA, Barrett JC, Lombardi B, Marco-Casanova P, Pierce AJ, Paulovich AG. Cancers (Basel). 2021 Jul 30;13(15):3843. doi: 10.3390/cancers13153843. PMID: 34359745


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Sciex 5500 QTRAP
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N L
LC
Eksigent 425
Column Packing
Reprosil
Column Dimensions
75um x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b15 (2+) 47.3 23.2 35.7 46.5 26.1 34.6 66.3 34.9 49.7 15 27 15
b8 (1+) 36.7 17 12.6 26.9 16.6 14.1 45.5 23.8 18.9 15 27 15
b9 (1+) 26 19.8 20 30.1 19.9 26.6 39.8 28.1 33.3 15 27 15
b10 (1+) 36.4 18.4 21.2 54.7 23 28 65.7 29.5 35.1 15 27 15
b11 (1+) 32.7 29.1 33.6 40.9 26.2 28.3 52.4 39.2 43.9 15 27 15
y9 (1+) 30.3 23.9 23 35 29.6 43.8 46.3 38 49.5 15 27 15
sum 16.5 8.8 10.3 16.8 12.3 12.3 23.5 15.1 16 15 27 15


Additional Resources and Comments


Assay Details for CPTAC-5931 Collapse assay details

Data source: Panorama

Official Gene Symbol
RAD9A
Peptide Modified Sequence
SPQGPSPVLAEDS[+79.966331]EGEG
Modification Type
Phospho (ST)
Protein - Site of Modification
388
Peptide - Site of Modification
13
Peptide Start
375
Peptide End
391
CPTAC ID
CPTAC-5931
Peptide Molecular Mass
1,734.6986
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Cell Lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition. Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, Ivey RG, Huang D, Lin C, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Kaczmarczyk JA, Blonder J, Reading JJ, Richardson CW, Hewitt SM, Garcia-Buntley SS, Bocik W, Hiltke T, Rodriguez H, Harrington EA, Barrett JC, Lombardi B, Marco-Casanova P, Pierce AJ, Paulovich AG. Cancers (Basel). 2021 Jul 30;13(15):3843. doi: 10.3390/cancers13153843. PMID: 34359745


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Sciex 5500 QTRAP
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N L
LC
Eksigent 425
Column Packing
Reprosil
Column Dimensions
75um x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y6-98 (1+) 42.2 22.4 8.9 63.6 30.5 12.3 76.3 37.8 15.2 15 27 15
b6 (1+) 50.8 19.8 8.5 39.6 22.6 16.5 64.4 30 18.6 15 27 15
b8 (1+) 24.3 9.9 6.6 28.9 13 12 37.8 16.3 13.7 15 27 15
b9 (1+) 42.9 15.1 5.1 48.9 18.5 11 65.1 23.9 12.1 15 27 15
b10 (1+) 53.5 20.6 7.2 49.3 24.5 12.4 72.8 32 14.3 15 27 15
b11 (1+) 48.1 18 11.4 56.1 23.6 12.4 73.9 29.7 16.8 15 27 15
b15-98 (2+) 56.6 30.6 12.9 55.1 33.4 15.9 79 45.3 20.5 15 27 15
sum 19.8 5.6 2 23.5 11.9 10.3 30.7 13.2 10.5 15 27 15


Additional Resources and Comments